NO323695B1 - Ny terapeutisk anvendelse av et tienylsykloheksylaminderivat, farmasoyitsk preparat og produkt derav - Google Patents

Ny terapeutisk anvendelse av et tienylsykloheksylaminderivat, farmasoyitsk preparat og produkt derav Download PDF

Info

Publication number: NO323695B1
Authority: NO; Norway
Prior art keywords: substance; thienylcyclohexylamine; substances; neurotoxin; anticonvulsant
Prior art date: 1996-12-06

Application number

NO19992726A

Other languages

English (en)

Norwegian (no)

Other versions

NO992726L (no

NO992726D0 (no

Inventor

Jean-Marc Kamenka

Guy Lallement

Arbigny Pierre Bernard D

Original Assignee

Sod Conseils Rech Applic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-06

Filing date

1999-06-04

Publication date

2007-06-25

1996-12-06 Priority claimed from FR9614996A external-priority patent/FR2756738B1/fr

1997-06-13 Priority claimed from FR9707361A external-priority patent/FR2764510B3/fr

1999-06-04 Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic

1999-06-04 Publication of NO992726D0 publication Critical patent/NO992726D0/no

1999-08-04 Publication of NO992726L publication Critical patent/NO992726L/no

2007-06-25 Publication of NO323695B1 publication Critical patent/NO323695B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
230000001225 therapeutic effect Effects 0.000 title description 4
239000008194 pharmaceutical composition Substances 0.000 title 1
239000000126 substance Substances 0.000 claims description 57
239000000047 product Substances 0.000 claims description 40
231100000566 intoxication Toxicity 0.000 claims description 39
230000035987 intoxication Effects 0.000 claims description 39
239000002581 neurotoxin Substances 0.000 claims description 22
231100000618 neurotoxin Toxicity 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 21
101710138657 Neurotoxin Proteins 0.000 claims description 20
231100000189 neurotoxic Toxicity 0.000 claims description 18
230000002887 neurotoxic effect Effects 0.000 claims description 18
102000003914 Cholinesterases Human genes 0.000 claims description 17
108090000322 Cholinesterases Proteins 0.000 claims description 17
230000001773 anti-convulsant effect Effects 0.000 claims description 17
239000001961 anticonvulsive agent Substances 0.000 claims description 17
229960003965 antiepileptics Drugs 0.000 claims description 17
230000001078 anti-cholinergic effect Effects 0.000 claims description 16
GRXKLBBBQUKJJZ-UHFFFAOYSA-N Soman Chemical group CC(C)(C)C(C)OP(C)(F)=O GRXKLBBBQUKJJZ-UHFFFAOYSA-N 0.000 claims description 12
239000013543 active substance Substances 0.000 claims description 9
RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical group CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 claims description 8
229960002290 pyridostigmine Drugs 0.000 claims description 8
DKFAAPPUYWQKKF-UHFFFAOYSA-N 1-(2-methyl-1-thiophen-2-ylcyclohexyl)piperidine Chemical compound CC1CCCCC1(C=1SC=CC=1)N1CCCCC1 DKFAAPPUYWQKKF-UHFFFAOYSA-N 0.000 claims description 7
239000000544 cholinesterase inhibitor Substances 0.000 claims description 7
229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 6
UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 6
-1 benzolidiazepines Chemical compound 0.000 claims description 6
229940079593 drug Drugs 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
JBKPUQTUERUYQE-UHFFFAOYSA-O pralidoxime Chemical compound C[N+]1=CC=CC=C1\C=N\O JBKPUQTUERUYQE-UHFFFAOYSA-O 0.000 claims description 6
229960003370 pralidoxime Drugs 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 4
230000000670 limiting effect Effects 0.000 claims description 4
230000002441 reversible effect Effects 0.000 claims description 4
239000002341 toxic gas Substances 0.000 claims description 4
229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 3
229930003347 Atropine Natural products 0.000 claims description 3
LTKOVYBBGBGKTA-SFHVURJKSA-N Avizafone Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N(C)C1=CC=C(Cl)C=C1C(=O)C1=CC=CC=C1 LTKOVYBBGBGKTA-SFHVURJKSA-N 0.000 claims description 3
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims description 3
STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 3
STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 3
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 3
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 claims description 3
FJZDLOMCEPUCII-UHFFFAOYSA-P [1-[(4-carbamoylpyridin-1-ium-1-yl)methoxymethyl]pyridin-2-ylidene]methyl-oxoazanium Chemical compound C1=CC(C(=O)N)=CC=[N+]1COCN1C(=C[NH+]=O)C=CC=C1 FJZDLOMCEPUCII-UHFFFAOYSA-P 0.000 claims description 3
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 3
229960000396 atropine Drugs 0.000 claims description 3
229940049706 benzodiazepine Drugs 0.000 claims description 3
229960000623 carbamazepine Drugs 0.000 claims description 3
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 3
CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 3
229960001403 clobazam Drugs 0.000 claims description 3
239000013066 combination product Substances 0.000 claims description 3
229940127555 combination product Drugs 0.000 claims description 3
NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
MNSQDVCVWNXBFQ-UHFFFAOYSA-N dihexyverine Chemical compound C1CCCCC1(C1CCCCC1)C(=O)OCCN1CCCCC1 MNSQDVCVWNXBFQ-UHFFFAOYSA-N 0.000 claims description 3
229960003215 dihexyverine Drugs 0.000 claims description 3
229960002767 ethosuximide Drugs 0.000 claims description 3
HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 claims description 3
229960002870 gabapentin Drugs 0.000 claims description 3
239000002917 insecticide Substances 0.000 claims description 3
229960003019 loprazolam Drugs 0.000 claims description 3
UTEFBSAVJNEPTR-RGEXLXHISA-N loprazolam Chemical compound C1CN(C)CCN1\C=C/1C(=O)N2C3=CC=C([N+]([O-])=O)C=C3C(C=3C(=CC=CC=3)Cl)=NCC2=N\1 UTEFBSAVJNEPTR-RGEXLXHISA-N 0.000 claims description 3
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 claims description 3
229960004429 obidoxime Drugs 0.000 claims description 3
HIGRLDNHDGYWQJ-UHFFFAOYSA-P obidoxime Chemical compound C1=CC(=C[NH+]=O)C=CN1COCN1C=CC(=C[NH+]=O)C=C1 HIGRLDNHDGYWQJ-UHFFFAOYSA-P 0.000 claims description 3
229960002695 phenobarbital Drugs 0.000 claims description 3
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 3
229960002036 phenytoin Drugs 0.000 claims description 3
229960001697 physostigmine Drugs 0.000 claims description 3
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 claims description 3
229960002393 primidone Drugs 0.000 claims description 3
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 claims description 3
108010055741 pro-diazepam Proteins 0.000 claims description 3
STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 3
229960002646 scopolamine Drugs 0.000 claims description 3
229940084026 sodium valproate Drugs 0.000 claims description 3
AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 3
PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 3
229960005318 vigabatrin Drugs 0.000 claims description 3
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
PJVJTCIRVMBVIA-JTQLQIEISA-N [dimethylamino(ethoxy)phosphoryl]formonitrile Chemical compound CCO[P@@](=O)(C#N)N(C)C PJVJTCIRVMBVIA-JTQLQIEISA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
150000001557 benzodiazepines Chemical class 0.000 claims description 2
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims description 2
229960003120 clonazepam Drugs 0.000 claims description 2
229930195712 glutamate Natural products 0.000 claims description 2
HGWPFSBHDACWNL-LZYIFBDPSA-N atropine oxyde Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2([O-])C)C(=O)C(CO)C1=CC=CC=C1 HGWPFSBHDACWNL-LZYIFBDPSA-N 0.000 claims 2
229950010917 atropine oxyde Drugs 0.000 claims 2
238000004519 manufacturing process Methods 0.000 claims 2
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
DYAHQFWOVKZOOW-UHFFFAOYSA-N Sarin Chemical compound CC(C)OP(C)(F)=O DYAHQFWOVKZOOW-UHFFFAOYSA-N 0.000 claims 1
JJIUCEJQJXNMHV-UHFFFAOYSA-N VX nerve agent Chemical compound CCOP(C)(=O)SCCN(C(C)C)C(C)C JJIUCEJQJXNMHV-UHFFFAOYSA-N 0.000 claims 1
241001465754 Metazoa Species 0.000 description 63
238000002474 experimental method Methods 0.000 description 10
206010010071 Coma Diseases 0.000 description 9
238000011084 recovery Methods 0.000 description 9
230000002981 neuropathic effect Effects 0.000 description 7
206010044565 Tremor Diseases 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
230000001537 neural effect Effects 0.000 description 6
230000002490 cerebral effect Effects 0.000 description 5
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
230000011514 reflex Effects 0.000 description 5
206010010904 Convulsion Diseases 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
241000288906 Primates Species 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000010253 intravenous injection Methods 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
208000034308 Grand mal convulsion Diseases 0.000 description 3
230000007059 acute toxicity Effects 0.000 description 3
231100000403 acute toxicity Toxicity 0.000 description 3
239000000203 mixture Substances 0.000 description 3
208000005809 status epilepticus Diseases 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
229940072690 valium Drugs 0.000 description 3
230000000007 visual effect Effects 0.000 description 3
LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 2
241000282567 Macaca fascicularis Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
208000006633 Tonic-Clonic Epilepsy Diseases 0.000 description 2
HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 2
229960002028 atropine sulfate Drugs 0.000 description 2
150000001540 azides Chemical class 0.000 description 2
230000001055 chewing effect Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000009795 derivation Methods 0.000 description 2
229960003529 diazepam Drugs 0.000 description 2
230000001037 epileptic effect Effects 0.000 description 2
210000001320 hippocampus Anatomy 0.000 description 2
238000010562 histological examination Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000034 method Methods 0.000 description 2
230000001936 parietal effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000033764 rhythmic process Effects 0.000 description 2
230000002123 temporal effect Effects 0.000 description 2
UJIKDMHWQDKDPV-UHFFFAOYSA-N 1-thiophen-2-ylcyclohexan-1-amine Chemical compound C=1C=CSC=1C1(N)CCCCC1 UJIKDMHWQDKDPV-UHFFFAOYSA-N 0.000 description 1
CMFDNSKEDGNBAL-UHFFFAOYSA-N 2-methyl-1-thiophen-2-ylcyclohexan-1-ol Chemical compound CC1CCCCC1(O)C1=CC=CS1 CMFDNSKEDGNBAL-UHFFFAOYSA-N 0.000 description 1
LFSAPCRASZRSKS-UHFFFAOYSA-N 2-methylcyclohexan-1-one Chemical compound CC1CCCCC1=O LFSAPCRASZRSKS-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
206010003497 Asphyxia Diseases 0.000 description 1
206010011703 Cyanosis Diseases 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
208000000059 Dyspnea Diseases 0.000 description 1
206010013975 Dyspnoeas Diseases 0.000 description 1
208000001308 Fasciculation Diseases 0.000 description 1
206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
HGWPFSBHDACWNL-GFBLOWMDSA-N [(1r,5s)-8-methyl-8-oxido-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate Chemical compound C([C@H]1CC[C@@H](C2)[N+]1([O-])C)C2OC(=O)C(CO)C1=CC=CC=C1 HGWPFSBHDACWNL-GFBLOWMDSA-N 0.000 description 1
ANAWDZDUNMBRQA-UHFFFAOYSA-N [Mg]C=1C=CSC=1Br Chemical compound [Mg]C=1C=CSC=1Br ANAWDZDUNMBRQA-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000002779 cholinesterase reactivator Substances 0.000 description 1
210000000078 claw Anatomy 0.000 description 1
230000009194 climbing Effects 0.000 description 1
230000002566 clonic effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000036461 convulsion Effects 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
210000001947 dentate gyrus Anatomy 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
208000027685 extreme exhaustion Diseases 0.000 description 1
230000004438 eyesight Effects 0.000 description 1
206010016256 fatigue Diseases 0.000 description 1
208000013403 hyperactivity Diseases 0.000 description 1
238000007654 immersion Methods 0.000 description 1
238000002513 implantation Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
230000003387 muscular Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000000324 neuroprotective effect Effects 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
230000008807 pathological lesion Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
238000004237 preparative chromatography Methods 0.000 description 1
208000018299 prostration Diseases 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000001644 thecoma Diseases 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO19992726A 1996-12-06 1999-06-04 Ny terapeutisk anvendelse av et tienylsykloheksylaminderivat, farmasoyitsk preparat og produkt derav NO323695B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR9614996A FR2756738B1 (fr)	1996-12-06	1996-12-06	Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
FR9707361A FR2764510B3 (fr)	1997-06-13	1997-06-13	Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine
PCT/FR1997/002219 WO1998024434A1 (fr)	1996-12-06	1997-12-05	Nouvelle application therapeutique d'un derive de la thienylcyclohexylamine

Publications (3)

Publication Number	Publication Date
NO992726D0 NO992726D0 (no)	1999-06-04
NO992726L NO992726L (no)	1999-08-04
NO323695B1 true NO323695B1 (no)	2007-06-25

Family

ID=26233146

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19992726A NO323695B1 (no)	1996-12-06	1999-06-04	Ny terapeutisk anvendelse av et tienylsykloheksylaminderivat, farmasoyitsk preparat og produkt derav

Country Status (20)

Country	Link
US (1)	US6207685B1 (da)
EP (1)	EP0956019B1 (da)
JP (1)	JP3859238B2 (da)
AR (1)	AR008536A1 (da)
AT (1)	ATE251907T1 (da)
AU (1)	AU734828B2 (da)
CA (1)	CA2274135C (da)
CZ (1)	CZ296245B6 (da)
DE (1)	DE69725613T2 (da)
DK (1)	DK0956019T3 (da)
ES (1)	ES2206762T3 (da)
IL (1)	IL130209A (da)
NO (1)	NO323695B1 (da)
PL (1)	PL191567B1 (da)
PT (1)	PT956019E (da)
RU (1)	RU2183456C2 (da)
SK (1)	SK285208B6 (da)
TR (1)	TR199901237T2 (da)
TW (1)	TW482674B (da)
WO (1)	WO1998024434A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6784194B2 (en) *	1996-12-06	2004-08-31	Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.)	Therapeutic use of a thienylcyclohexylamine derivative
DK1169060T3 (da) *	1999-04-09	2006-01-16	Euro Celtique Sa	Natriumkanalblokkerpræparater og anvendelse deraf
DK1423168T3 (da) *	2001-09-03	2006-05-15	Newron Pharm Spa	Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
RU2216324C1 (ru) *	2002-09-16	2003-11-20	Катаев Валерий Алексеевич	Вещество, повышающее физическую работоспособность в условиях отравления фосфорорганическими соединениями
GB0322140D0 (en) *	2003-09-22	2003-10-22	Pfizer Ltd	Combinations
DK1809271T5 (da) *	2004-09-10	2010-12-06	Newron Pharm Spa	Anvendelse af (R)-(halogenbenzyloxy)benzylaminopropanamider som natrium- og/eller calciumkanalselektive modulatorer
EP1963280B1 (en)	2005-12-22	2015-10-28	Newron Pharmaceuticals S.p.A.	2-phenylethylamino derivatives as calcium and/or sodium channel modulators

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0317953A3 (en)	1987-11-24	1990-12-05	G.D. Searle & Co.	N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury
US5604255A (en) *	1987-11-24	1997-02-18	The United States Of America As Represented By The Department Of Health And Human Services	N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury
FR2639225B1 (fr) *	1988-11-21	1993-05-21	Centre Nat Rech Scient	Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
FR2661783A1 (fr)	1990-05-02	1991-11-08	Monerie Michel	Dispositif optique, pour l'emission et l'amplification de lumiere dans la gamme 1260-1234nm, a milieu actif contenant du praseodyme.
ZA922180B (en) *	1991-03-29	1993-09-27	Lilly Co Eli	Piperidine derivatives

1997
- 1997-05-12 US US09/180,384 patent/US6207685B1/en not_active Expired - Fee Related
- 1997-12-04 AR ARP970105705A patent/AR008536A1/es not_active Application Discontinuation
- 1997-12-05 CA CA002274135A patent/CA2274135C/fr not_active Expired - Fee Related
- 1997-12-05 AU AU53266/98A patent/AU734828B2/en not_active Ceased
- 1997-12-05 JP JP52529798A patent/JP3859238B2/ja not_active Expired - Fee Related
- 1997-12-05 AT AT97950237T patent/ATE251907T1/de active
- 1997-12-05 WO PCT/FR1997/002219 patent/WO1998024434A1/fr not_active Ceased
- 1997-12-05 DE DE69725613T patent/DE69725613T2/de not_active Expired - Lifetime
- 1997-12-05 TR TR1999/01237T patent/TR199901237T2/xx unknown
- 1997-12-05 IL IL13020997A patent/IL130209A/xx not_active IP Right Cessation
- 1997-12-05 PL PL334103A patent/PL191567B1/pl not_active IP Right Cessation
- 1997-12-05 EP EP97950237A patent/EP0956019B1/fr not_active Expired - Lifetime
- 1997-12-05 DK DK97950237T patent/DK0956019T3/da active
- 1997-12-05 PT PT97950237T patent/PT956019E/pt unknown
- 1997-12-05 ES ES97950237T patent/ES2206762T3/es not_active Expired - Lifetime
- 1997-12-05 CZ CZ0198999A patent/CZ296245B6/cs not_active IP Right Cessation
- 1997-12-05 SK SK743-99A patent/SK285208B6/sk not_active IP Right Cessation
- 1997-12-05 RU RU99114853/14A patent/RU2183456C2/ru not_active IP Right Cessation
- 1997-12-27 TW TW086118430A patent/TW482674B/zh not_active IP Right Cessation
1999
- 1999-06-04 NO NO19992726A patent/NO323695B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
AU734828B2 (en)	2001-06-21
SK285208B6 (sk)	2006-08-03
PT956019E (pt)	2004-03-31
US6207685B1 (en)	2001-03-27
SK74399A3 (en)	2000-05-16
PL334103A1 (en)	2000-01-31
ATE251907T1 (de)	2003-11-15
EP0956019B1 (fr)	2003-10-15
AU5326698A (en)	1998-06-29
WO1998024434A1 (fr)	1998-06-11
DK0956019T3 (da)	2004-02-16
CZ296245B6 (cs)	2006-02-15
CA2274135C (fr)	2006-08-15
PL191567B1 (pl)	2006-06-30
JP2001505217A (ja)	2001-04-17
NO992726L (no)	1999-08-04
DE69725613D1 (de)	2003-11-20
DE69725613T2 (de)	2004-09-16
IL130209A0 (en)	2000-06-01
ES2206762T3 (es)	2004-05-16
JP3859238B2 (ja)	2006-12-20
TR199901237T2 (xx)	1999-08-23
EP0956019A1 (fr)	1999-11-17
AR008536A1 (es)	2000-01-19
NO992726D0 (no)	1999-06-04
IL130209A (en)	2003-07-06
CA2274135A1 (fr)	1998-06-11
CZ198999A3 (cs)	2000-06-14
RU2183456C2 (ru)	2002-06-20
TW482674B (en)	2002-04-11

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
Drukarch et al.	1987	9-Amino-1, 2, 3, 4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current
RU2338537C2 (ru)	2008-11-20	СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
Shih et al.	2007	Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine
EP1600168A2 (en)	2005-11-30	A pyrrolidineacetamide derivative alone or in combination for treatment of CNS disorder
Gilat et al.	2005	Anticonvulsant treatment of sarin-induced seizures with nasal midazolam: an electrographic, behavioral, and histological study in freely moving rats
US5447952A (en)	1995-09-05	Treatment of anxiety with the aid of (S)-(-)-α-ethyl-2-oxo-1-pyrrolidineacetamide
US20230098667A1 (en)	2023-03-30	Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
NO323695B1 (no)	2007-06-25	Ny terapeutisk anvendelse av et tienylsykloheksylaminderivat, farmasoyitsk preparat og produkt derav
McCall et al.	1995	Comparison of the efficacy of titrated, moderate-dose and fixed, high-dose right unilateral ECT in elderly patients
Itoh et al.	1997	Effects of metrifonate on memory impairment and cholinergic dysfunction in rats
KR20020068404A (ko)	2002-08-27	미르타자핀을 포함하는, 우울증 및 관련 장애 치료용 약물조합물
US6541513B2 (en)	2003-04-01	Carbamate compounds for use in preventing or treating psychotic disorders
CA3124416C (en)	2023-05-23	Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
AU2002242296A1 (en)	2003-03-06	Carbamate compounds for use in preventing or treating psychotic disorders
AU2005289808B2 (en)	2011-11-03	Method of treating organophosphorous poisoning
US20010056091A1 (en)	2001-12-27	Therapeutic use of a thienylcyclohexylamine derivative
US5747494A (en)	1998-05-05	Pharmaceutical compositions for the treatment of depressive disorders
Miller et al.	1992	Therapeutic frontiers in Alzheimer's disease
HUP0001457A2 (hu)	2000-11-28	Tienilciklohexilamin-származék új gyógyászati alkalmazása
HK40063144B (en)	2025-03-14	Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
HK40063144A (en)	2022-06-17	Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
Feiner et al.	2011	Seizures and Other Neurological Symptoms Induced by Organophosphates, Including Warfare Nerve Agents
Kertész et al.	2007	P. 1. c. 044 Improvement of AMPA antagonist activity by methyl substitution on the aniline ring of 2, 3-benzodiazepine derivatives
Poschel	2013	NEW PHARMACOLOGICAL PERSPECTIVES ON NOOTROPIC
Silverman	0	Nootropic Drugs